Credit rating agency, CARE has revised ‘AA’ rating to Ranbaxy Laboratories’ Long-term Bank Facilities worth Rs 300 crore and Long-term Instrument (NCD) worth Rs 500 crore from AA+. The rating agency has also reaffirmed ‘A1+’Short-term Bank Facilities worth Rs 600 crore.
The company has received the said ratings on the back of its established position in the domestic pharmaceuticals market and in the global markets supported by a pipeline of Abbreviated New Drug Applications (ANDAs)
Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
